Catena Biosciences

Revolutionary technology to make new protein based therapies

What is the Challenge?

Protein-based therapies represent an expanding majority of treatments prescribed today. Therapeutic proteins can be used to replace a protein that is abnormal or deficient in a particular disease, and are genetically engineered versions of naturally occurring human proteins. Any new protein-based drug designs take up to 12 months to produce before they can even begin testing for therapeutic activity. This leads to slower and more expensive development of better therapeutics. As the rates of diseases and conditions continue to climb and total spending on treatments worldwide increases, the need for a game changer in therapeutic discovery has never been greater.

What is the Solution?

US-based biotech Catena Biosciences’s revolutionary protein coupling platform re-defines the potential of biotherapeutics. The development of their novel bio-chemical reaction technology began at Berkeley, US, in 2004. In recent years, through an unintentional discovery, it was found that a modified enzyme could quickly and efficiently bring full-sized proteins together.

Their proprietary enzyme allows for a faster, specific, and durable linking of any two or more proteins without disrupting their core function. This could include large, complex proteins not suitable for traditional coupling approaches without extensive modification. To ensure an optimal therapeutic drug design, they leverage their platform’s ability to modularly combine proteins and control orientation through positional flexibility. Catena Biosciences’s platform uses only naturally occurring amino acids and can be used to create complicated constructs far beyond the capability of traditional genetic fusions or chemical attachment found in the industry today. By using this technique, scientists can now address unmet needs in diseases like oncology, autoimmune, and regenerative therapy.

Latest